Skip to content
Open access

Prognostic impact of HLA-G expression in cervical squamous cell carcinoma: correlation with PD-L1 and CD8-positive tumor infiltrating lymphocytes

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 35 references
Medicine

Abstract

Background Purpose of the study was to investigate the prognostic impact of HLA-G expression in patients with cervical squamous cell carcinoma (CSCC), and to further analyze its correlations with PD-L1 and CD8-positive (CD8+) tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment (TME). Methods A total of 139 formalin-fixed paraffin-embedded (FFPE) tissue samples were collected from patients diagnosed with CSCC. Immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) staining were performed to assess the expression of immune biomarkers, including HLA-G, its receptor ILT2, PD-L1, total TILs and CD8+ TILs. Results The overall positive expression rates were 86.8% for HLA-G, 85.1% for sHLA-G, 50.0% for PD-L1, and 70.2% for cases with low TIL infiltration in the TME. These immune biomarkers displayed distinct immunoreactivity patterns with remarkable intratumoral and stromal heterogeneity. ILT2 expression was positively correlated with CD8+ TIL infiltration in both intratumoral and stromal compartments, yet rare cellular co-localization between ILT2 and CD8 was detected. Within tumoral regions, a strong positive correlation was identified between HLA-G and PD-L1 expression, and the two proteins were confirmed to be co-localized at the single-cell level in SCC lesions. Using the median HLA-G expression level of 61.0% as the cutoff value, patients with HLA-G expression above this threshold showed significantly worse overall survival (OS). The subgroup with high HLA-G/sHLA-G and low TIL infiltration showed the worst prognosis. Conclusions The present study confirms that elevated HLA-G/sHLA-G expression serves as an independent adverse prognostic factor for cervical cancer. Combined assessment of HLA-G, PD-L1 and TIL infiltration may enable risk-stratified prognostic management for patients with cervical cancer.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.